Trials / Completed
CompletedNCT01416402
Open Label Safety/Efficacy Study of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Gout Patients
A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of Arhalofenate (MBX-102) in Combination With Febuxostat for the Treatment of Hyperuricemia in Patients With Gout
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether arhalofenate is safe and effective when dosed in combination with febuxostat in lowering serum uric acid in patients with gout.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Arhalofenate | 400 mg once daily orally for two weeks then up-titrated to 600 mg once daily orally for an additional two weeks |
| DRUG | Febuxostat | 80 mg once daily orally for 5 weeks |
| DRUG | Colchicine | Colchicine 0.6 mg daily as prophylaxis to prevent gout flares |
Timeline
- Start date
- 2011-08-01
- Primary completion
- 2011-10-01
- Completion
- 2011-10-01
- First posted
- 2011-08-15
- Last updated
- 2015-04-03
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01416402. Inclusion in this directory is not an endorsement.